A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients

By Hardy J.   Daly S.   McQuade B.   Albertsson M.   Chimontsi-Kypriou V.   Stathopoulos G.   Curtis P.  

Supportive Care in Cancer, Vol. 10, Iss. 3, 2002-04 ,pp. : 231-236

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m2 for the treatment of non-small cell lung cancer

By                        

Experimental and Therapeutic Medicine, Vol. 4, Iss. 2, 2012-01 ,pp. : 317-322

Spandidos Publications

Access to resources Recommend Favorite

Phase 2 Trial of Liposomal Doxorubicin (40 mg/m 2 ) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum

By Markman M.   Kennedy A.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 78, Iss. 3, 2000-09 ,pp. : 369-372

Elsevier

Access to resources Recommend Favorite

Results of a phase II trial with second-line cystemustine at 60mg/m 2 in advanced soft tissue sarcoma: A trial of the EORTC early clinical studies group

By Cure H.   Krakowski I.   Adenis A.   Tubiana N.   Kerbrat P.   Roche H.   Chevallier   Lentz M.A.   Fumoleau P.   Chollet P.  

European Journal of Cancer, Vol. 34, Iss. 3, 1998-02 ,pp. : 422-423

Elsevier

Access to resources Recommend Favorite

Japanese experience with second-line chemotherapy with low-dose (60 mg/m) docetaxel in patients with advanced non-small-cell lung cancer

By Mukohara Toru   Takeda Koji   Miyazaki Masaki   Takifuji Nobuhide   Terakawa Kazuhiko   Negoro Shunichi  

Cancer Chemotherapy and Pharmacology, Vol. 48, Iss. 5, 2001-11 ,pp. : 356-360

Springer Publishing Company

Access to resources Recommend Favorite